Efficacy and Endocrine Effects of Medical Treatment of Endometriosis
- 1 May 1991
- journal article
- research article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 622 (1), 275-282
- https://doi.org/10.1111/j.1749-6632.1991.tb37871.x
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Endocrine, metabolic, and clinical effects of gestrinone in women with endometriosisFertility and Sterility, 1989
- Prevention of follicular maturation in endometriosis by subcutaneous infusion of luteinizing hormone-releasing hormone agonist started in the luteal phaseFertility and Sterility, 1988
- Revised American Fertility Society Classification of Endometriosis: 1985Fertility and Sterility, 1985
- Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosisFertility and Sterility, 1984
- Treatment of endometriosis with gestrinone (R-2323), a synthetic antiestrogen, antiprogesteroneAmerican Journal of Obstetrics and Gynecology, 1982
- Danazol: Endocrine pharmacology and therapeutic applicationsAmerican Journal of Obstetrics and Gynecology, 1981
- Endocrine Properties and Clinical Application of DanazolFertility and Sterility, 1979
- Management of Endometriosis in the Infertile PatientFertility and Sterility, 1975
- Clinical Studies with an Antigonadotropin-DanazolFertility and Sterility, 1971
- The use of newer progestins in the treatment of endometriosisAmerican Journal of Obstetrics and Gynecology, 1958